265 related articles for article (PubMed ID: 33162471)
1. Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly.
Fukunaga K; Imachi H; Sato S; Kobayashi T; Yoshioka Y; Saheki T; Ban N; Urushihara K; Lyu J; Dong T; Ishikawa R; Kadota K; Haba R; Inoshita N; Murao K
Intern Med; 2021 Apr; 60(7):1047-1053. PubMed ID: 33162471
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
3. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
Silverstein JM
Pituitary; 2016 Oct; 19(5):536-43. PubMed ID: 27405306
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
Ben-Shlomo A; Melmed S
IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide-a novel somatostatin receptor ligand after 20 years of use.
Bolanowski M; Kałużny M; Witek P; Jawiarczyk-Przybyłowska A
Rev Endocr Metab Disord; 2022 Jun; 23(3):601-620. PubMed ID: 35067849
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment:
Feldt-Rasmussen U; Bolanowski M; Zhang SL; Yu Y; Witek P; Kalra P; Kietsiriroje N; Piacentini A; Pedroncelli AM; Samson SL
Front Endocrinol (Lausanne); 2024; 15():1250822. PubMed ID: 38577574
[TBL] [Abstract][Full Text] [Related]
7. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
8. Pasireotide therapy in a rare and unusual case of plurihormonal pituitary macroadenoma.
Rajendran R; Naik S; Sandeman DD; Nasruddin AB
Endocrinol Diabetes Metab Case Rep; 2013; 2013():130026. PubMed ID: 24616766
[TBL] [Abstract][Full Text] [Related]
9. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas.
Regazzo D; Avallone S; MacSweeney CP; Sergeev E; Howe D; Godwood A; Bennett KA; Brown AJH; Barnes M; Occhi G; Barbot M; Faggian D; Tropeano MP; Losa M; Lasio G; Scaroni C; Pecori Giraldi F
Eur J Endocrinol; 2024 Jan; 190(1):K8-K16. PubMed ID: 38123488
[TBL] [Abstract][Full Text] [Related]
10. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Petersenn S; Salgado LR; Schopohl J; Portocarrero-Ortiz L; Arnaldi G; Lacroix A; Scaroni C; Ravichandran S; Kandra A; Biller BMK
Endocrine; 2017 Jul; 57(1):156-165. PubMed ID: 28597198
[TBL] [Abstract][Full Text] [Related]
12. Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report.
Takiguchi T; Koide H; Nagano H; Nakayama A; Fujimoto M; Tamura A; Komai E; Shiga A; Kono T; Higuchi S; Sakuma I; Hashimoto N; Suzuki S; Miyabayashi Y; Ishiwatari N; Horiguchi K; Nakatani Y; Yokote K; Tanaka T
BMC Endocr Disord; 2017 Sep; 17(1):54. PubMed ID: 28865461
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide: a review of its use in Cushing's disease.
McKeage K
Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide (SOM230): development, mechanism of action and potential applications.
Schmid HA
Mol Cell Endocrinol; 2008 May; 286(1-2):69-74. PubMed ID: 17977644
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Opposite Tumoral and Hormonal Responses to Low-dose Pasireotide in Cushing's Disease.
Serban AL; Zampetti B; Saladino A; Favero V; Chiodini I; Cozzi R
Endocr Metab Immune Disord Drug Targets; 2024; 24(7):845-849. PubMed ID: 37937561
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
[TBL] [Abstract][Full Text] [Related]
17. Plurihormonal pituitary adenoma cosecreting ACTH and GH: a rare cause of Cushing's disease.
Amir J; Guiot MC; Garfield N
BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36410786
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide - Mechanism of Action and Clinical Applications.
Sawicka-Gutaj N; Owecki M; Ruchala M
Curr Drug Metab; 2018; 19(10):876-882. PubMed ID: 29595102
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
Cannavo S; Messina E; Albani A; Ferrau F; Barresi V; Priola S; Esposito F; Angileri F
Endocrine; 2016 Jun; 52(3):481-7. PubMed ID: 25877016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
